Stroke Drug Development Services

Currently, tissue plasminogen activator (tPA) is the gold standard for ischemic stroke in clinical practice. However, a shorter therapeutic window of opportunity limits the utility of tPA. Secondary brain damage from stroke is also a pressing issue. Many organizations have invested significant funds and resources in the development of new drugs to improve quality of life, but most have failed in clinical practice. In addition, the traditional process of stroke drug development is very costly and has a high failure rate. In conclusion, the development of stroke drugs is very urgent and necessary.

Fig. 1. Ischemic stroke research: from basic investigation to clinical application. Fig. 1. Ischemic stroke translational research: from basic investigation to clinical application. (Chen et al., 2024)

Integrated Stroke Drug Development Services

Ace Therapeutics is a leading provider of preclinical stroke research services, specializing in providing comprehensive and customized stroke drug development services to pharmaceutical companies, biotech firms, and academic researchers. With one-stop services from target discovery and validation to preclinical evaluation, we aim to accelerate our clients' stroke therapy development programs.

Target Identification and Validation

Our team employs a multi-faceted approach that integrates advanced genomic, proteomic, and bioinformatics tools to identify and validate potential targets that play a key role in stroke pathogenesis, such as those involved in inflammation, oxidative stress, and neuronal cell death.

Categories	Promising therapeutic targets
Targeting excitotoxicity	NMDA receptor (NMDAR), AMPA receptor (AMPAR), metabotropic glutamate receptor (mGluR), glutamate receptor, γ-amino butyric acid (GABA) receptor, PSD-95, etc.
Targeting oxidative stress	Superoxide dismutase (SOD), catalase (CAT), peroxidase, glutathione peroxidase (GSH-Px), etc.
Targeting apoptosis	Bcl-2 protein family, p53 gene, caspase family, Fas gene, JAK2/STAT3 signaling pathway, etc.
Targeting autophagy	HIF-1α/BNIP3, PINK1/Parkin, PKC/JNK, PI3K/Akt-mTOR, AMPK/mTORC1, etc.
Targeting inflammation	Interleukin 1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), NLRP3, etc.
Targeting angiogenesis	Vascular endothelial growth factor (VEGF), angiogenin, platelet-derived growth factor (PDGF), transforming growth factor (TGF), basic fibroblast growth factor (bFGF), matrix metalloproteinases (MMPs), hepatocyte growth factor (HGF), nitric oxide (NO), etc.
Targeting neurogenesis	Brain-derived neurotrophic factor (BDNF) pathway, Notch pathway, Wnt/β-Catenin pathway, bone morphogenetic protein (BMP) pathway, etc.

In Vitro and In Vivo Studies

Cell-based assays: We use primary neuronal cultures, glial cells, and endothelial cells to study mechanisms such as neuroinflammation, blood-brain barrier (BBB) dysfunction, and neuronal apoptosis.
3D cell cultures and organoids: We provide advanced 3D cell cultures and brain organoids to better mimic the complexity of the brain's microenvironment. These innovative models provide a powerful platform for studying stroke pathophysiology and evaluating the efficacy of potential therapeutics.
Animal models: Ace Therapeutics offers a wide range of preclinical models, including transient and permanent middle cerebral artery occlusion (MCAO), photothrombotic stroke, and embolic stroke models. These models are complemented by advanced imaging techniques (e.g., MRI, PET) and behavioral assessments to provide a comprehensive evaluation of drug efficacy and safety.

Pharmacokinetics and Pharmacodynamics (PK/PD) Studies

Our team can help clients conduct detailed PK/PD studies to assess the absorption, distribution, metabolism, and excretion (ADME) of potential stroke therapeutics. These include assessing bioavailability, tissue penetration (e.g., across the blood-brain barrier), and metabolic stability.

Types of Stroke Drugs We Can Develop

At Ace Therapeutics, we understand the complexities of stroke pathophysiology and the challenges associated with developing effective therapeutics. With deep expertise in discovery informatics, computational chemistry, molecular modeling, medicinal chemistry, structural biology, in vitro and in vivo pharmacology, and translational science in the field of stroke, Ace Therapeutics provides end-to-end support for stroke drug development.

By Drug Modality	Small Molecule Drugs for Stroke Neuropeptides Monoclonal Antibodies for Stroke Stem Cell-Based Therapies for Stroke
By Drug Action	Neuroprotective Agents Against Stroke Thrombolytics for Stroke Anticoagulant Drugs Antiplatelet Drugs for Stroke

Why Choose Us

Study design. We work with clients to develop the most appropriate study design based on their specific objectives.
Data analysis. We use state-of-the-art methods to analyze the data from our studies and provide our clients with clear and concise reports.
Experimental model development. We provide a wide range of preclinical stroke models to help clients develop the potential of new drug candidates.
In-depth expertise. Our team of specialists has extensive knowledge in a variety of fields, including imaging, neurology, and hemodynamics.

Ace Therapeutics provide one-stop drug development services designed to help clients rapidly achieve key milestones in the development of innovative stroke therapeutics. If you are looking for a high-quality solution with best practices in the field of stroke drug development, please feel free to contact us.

Reference

Chen, W., et al. (2024). New drug developments for stroke: from basics to clinics. Translational Stroke Research, 15(2), 335-338.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.